Most Read

The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell

The phase III clinical trials will assess the efficacy and safety of the CoronaVac vaccine candidate, which is developed by Sinovac Life Sciences. Sinovac’s case-driven, randomised, double-blinded and

The CheckMate -649 trial demonstrated statistically significant and clinically meaningful improvement in both the parameters for the Opdivo + chemotherapy arm compared to chemotherapy alone. The late-stage trial

The deal also allows Inflazome to secure additional contingent payments based on the achievement of certain predetermined milestones. Based in Dublin, Inflazome is engaged in the development of

The global trial called EV-301 compared PADCEV to chemotherapy in nearly 600 patients who had prior treatment with platinum-based chemotherapy and a PD-1/L1 inhibitor. Co-developed by the two

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is

As part of the partnership, RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s, after securing regulatory approval in India. Developed by the Gamaleya National

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour